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Steroid hormone receptors generally refer to
ligand-dependent transcriptional regulators
controlling the activity of specific gene net-
works involved in endocrine function (Ing
and O’Malley 1995). Evidence is accumulat-
ing that some man-made compounds may
disrupt normal endocrine function by binding
to steroid hormone receptors. Xenoestrogens,
for example, not only appear to modulate
estrogen-responsive endocrine functions but
may also stimulate the growth of estrogen-
dependent tumors (Safe and Zacharewski
1997; Wolff and Toniolo 1995). In addition,
there are reports of environmental contami-
nants capable of interfering with androgen
receptor (AR) function. These include chemi-
cals such as the herbicide linuron (Gray et al.
1999c; McIntyre et al. 2000), metabolites of
the fungicides vinclozolin (Gray et al. 1999b;
Kelce et al. 1994; Monosson et al. 1999; Wong
et al. 1995) and procymidone (Mekenyan et al.
1997; Ostby et al. 1999; Waller et al. 1996a),
the insecticide methoxychlor (Gray et al.
1999a) and its metabolite HPTE (Maness et
al. 1998), and the DDT metabolite p,p´-DDE
(Gray et al. 1999c; Kelce et al. 1995). The
structural diversity of these chemicals, many
in widespread use, has heightened concern
about the potential of other environmental
chemicals to disrupt AR function and has led
to the development of models and strategies
for predicting potential AR activity from
chemical structure (Mekenyan et al. 1997;
Waller et al. 1996a).
Quantitative structure–activity relation-
ship (QSAR) models and qualitative SAR
approaches have had some success in identify-
ing and depicting structural features that con-
tribute to the ability of a chemical to interact
with steroid hormones, for both the estrogen
receptor (ER) (Anstead et al. 1997; Fang et al.
2001; McKinney and Waller 1994; Tong et
al. 1997a, 1997b, 1998; Waller et al. 1996b;
Wiese and Brooks 1994) and the AR
(Loughney and Schwender 1992; Mekenyan
et al. 1997; Singh et al. 2000; Tucker et al.
1988; Waller et al. 1996a). In the case of envi-
ronmentally occurring chemicals, studies have
revealed a common pattern of steric and elec-
tronic features involved in molecular recogni-
tion and receptor binding afﬁnity, in spite of
the molecular diversity of such data sets. Of
particular interest to the present study are
structural elements important in interactions
of nonsteroidal ligands with the AR. Multiple
lines of evidence indicate that a substituted
phenyl ring, denoted the A-ring in Figure 1, is
an essential structural feature in that it acts as
an anchor to the molecular recognition site of
AR and ER receptors (Anstead et al. 1997;
Brzozowski et al. 1997; Marhefka et al. 2001;
McKinney and Waller 1994; Mekenyan et al.
1997; Pike et al. 1999; Poujol et al. 2000;
Waller et al. 1996a). In addition, QSAR mod-
els have shown that increased negative charge
in the vicinity of the A-ring off the C3 atoms
is correlated with increased AR binding afﬁn-
ity (Mekenyan et al. 1997; Waller et al.
1996a). The greatest structural variations in
nonsteroidal AR ligands appear in the molecu-
lar region that corresponds to the D-ring
C17β hydroxyl region (Figure 1) of the nat-
ural ligand, dihydrotestosterone (DHT). In
this region, QSAR studies ﬁnd an increase in
AR binding afﬁnity correlates with increased
negative charge of substituents, and a decrease
in AR binding affinity correlates with an
increase in steric bulk (Mekenyan et al. 1997;
Waller et al. 1996a).
Also pertinent to discerning the structural
requirements of AR activity are the results of
studies aimed at optimizing antiandrogenic
function for the design of pharmaceuticals
(Singh et al. 2000; Teutsch et al. 1994;
Tucker et al. 1988). The essential rules for
antiandrogenic function extracted from these
studies are a) an electron-deficient aromatic
ring with a strong hydrogen bond (H bond)
acceptor (e.g., a nitro or cyano); and b) an
aryl-amide linkage to a carbon hosting a
strong H-bond donor group at the opposite
terminus of the ligand (see, e.g., the essential
structural moiety depicted in Figure 2). More
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Identification of several environmental chemicals capable of binding to the androgen receptor
(AR) and interfering with its normal function has heightened concern about adverse effects across
a broad spectrum of environmental chemicals. We previously demonstrated AR antagonist activity
of the organophosphate (OP) pesticide fenitrothion. In this study, we characterized AR activity of
analogues of fenitrothion to probe the structural requirements for AR activity among related
chemicals. AR activity was measured using HepG2 human hepatoma cells transfected with human
AR plus an androgen-responsive luciferase reporter gene, MMTV-luc. AR antagonist activity
decreased as alkyl chain length of the phosphoester increased, whereas electron-donating proper-
ties of phenyl substituents of the tested compounds did not inﬂuence AR activity. Oxon deriva-
tives of fenitrothion, which are more likely to undergo hydrolytic degradation, had no detectable
AR antagonist activity. Molecular modeling results suggest that hydrogen-bond energies and the
maximum achievable interatomic distance between two terminal H-bond capable sites may inﬂu-
ence both the potential to interact with the AR and the nature of the interaction (agonist vs.
antagonist) within this series of chemicals. This hypothesis is supported by the results of recent
AR homology modeling and crystallographic studies relative to agonist- and antagonist-bound AR
complexes. The present results are placed in the context of structure–activity knowledge derived
from previous modeling studies as well as studies aimed toward designing nonsteroidal antiandrogen
pharmaceuticals. Present results extend understanding of the structural requirements for AR activity
to a new class of nonsteroidal, environmental, OP-related chemicals. Key words: androgen receptor,
fenitrothion, homology model, HepG2 cells, organophosphates, structure–activity relationships.
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Research | Articlesrecent publications have reported detailed
crystal structures and homology models of
AR, ER, and progesterone receptor (PR) lig-
and binding domains (LBD) with bound
agonist or antagonist ligands. These studies
have provided insight into steroid–ligand
binding speciﬁcity (e.g., AR vs. PR) as well as
information on specific residue interactions
within the LBD for steroidal and non-
steroidal bound ligands (Brzozowski et al.
1997; Marhefka et al. 2001; Matias et al.
2000; Pike et al. 1999; Poujol et al. 2000;
Tanenbaum et al. 1998). Taken together,
QSAR models and AR binding studies paint
a consistent picture of polar substituents at
opposite termini of a nonsteroidal ligand
framework forming H bonds with appropri-
ate amino acid residues within the binding
pocket of the AR.
We investigated the antiandrogenic activity
of the organophosphate insecticide fenitroth-
ion [O,O-dimethyl-O-(3-methyl-4 nitro-
phenyl) phosphorothionate]. Fenitrothion is
currently registered by the U.S. Environmental
Protection Agency (U. S. EPA) only for non-
food uses (e.g., on terrestrial and greenhouse
plants and in rat and roach baits), whereas in
Japan there is extensive application of feni-
trothion to food crops such as rice and fruit
[estimated production of 1,230 tons for the
year 2000, with estimated half-lives of 22 days
and 84 days (at pH 7, 22°C) in soil and water,
respectively, and a bioconcentration factor of
246]. Fenitrothion has apparent structural
similarities with the pharmaceutical anti-
androgen flutamide and the environmental
antiandrogens vinclozolin and linuron (Figure
2) but differs most significantly in having a
thiophosphonyl group as a proposed H-bond
acceptor in the D-ring region of the AR inter-
action site. We have demonstrated that feni-
trothion acts as an AR competitive antagonist
in vitro and inhibits the development of
androgen-dependent tissues in vivo (Tamura
et al. 2001). In addition, we have reported
that fenitrothion, similar to hydroxy-
ﬂutamide, demonstrated weak agonist activity
at high doses in a noncompetitive binding
assay. To gain a better understanding of the
structural requirements for AR activity for
organophosphate-like chemicals, we investi-
gate here the AR activity of a number of com-
pounds structurally related to fenitrothion
and to other known AR antagonists such as
ﬂutamide and linuron (Figure 2). The results
of this study point to common structural
elements necessary for AR antagonist activity
and indicate that differences in H-bond prop-
erties and the distance between two capable
H-bond sites can account for differences in
the nature of the AR activity within this class
of antiandrogenic compounds. We consider
our findings in the context of recently pub-
lished crystallographic and homology models
of the AR-LBD, as well as in relation to prior
SAR studies and current hypotheses regarding
the structural basis for antiandrogenic activity
of nonsteroidal chemicals.
Materials and Methods
Chemicals. Fenitrothion, methyl parathion,
and 3-methyl-4-nitrophenol were obtained
from Chem Service (West Chester, PA,
USA). Other organophosphorus derivatives
were synthesized according to published
methods (Nishizawa et al. 1961). The struc-
ture of the synthesized compounds was deter-
mined as follows: 1H NMR spectra were
obtained on a JEOL EX400 spectrometer
(JEOL, Tokyo, Japan) using tetramethyl-
silane as an internal standard. Infrared and
UV spectra were recorded on a Perkin-Elmer
Spectrum RX III FT-IR (Perkin-Elmer,
Beaconsﬁeld, Bucks, UK) and Shimadzu UV-
240 spectrophotometer (Shimadzu, Kyoto,
Japan), respectively. Spectral data were consis-
tent with assigned structures. Refractive index
was measured using a 1T Abbe Refractometer
(ATAGO Co., Tokyo, Japan). All other chem-
icals were obtained from Sigma Chemical
Company (St. Louis, MO, USA). All chemi-
cals were > 97% pure.
Plating and transfection. We performed
transfection experiments as previously
described (Maness et al. 1998; Tamura et al.
2001). Brieﬂy, human hepatoma HepG2 cells
(ATCC, Rockville, MD, USA) were plated in
triplicate in 24-well plates (Falcon Plastics,
Oxnard, CA, USA) at a density of 105
cells/well in complete medium (phenol red-
free Eagle’s minimal essential medium;
GIBCO/BRL, Grand Island, NY, USA) sup-
plemented with 10% resin-stripped fetal
bovine serum (Hyclone, Logan, UT, USA),
2% L-glutamine, and 0.1% sodium pyruvate
and allowed to incubate overnight at 37°C in
a humidified atmosphere of 5% CO2/air.
Cells were then transfected as previously
described (Maness et al. 1998) (SuperFect;
Qiagen, Valencia, CA, USA, or TransIT;
Mirus Co., Madison, WI, USA) with three
plasmids: a) 10 ng/well human AR, b) 405
ng/well MMTV-luc reporter plasmid, and
c) 40 ng/well pCMVβ-gal plasmid as a trans-
fection and toxicity control. Cells were placed
in a 37°C incubator with a humidiﬁed atmos-
phere of 5% CO2/air for 3 hr. The transfected
cells were then rinsed with phosphate-buffered
saline and treated with various concentrations
of test chemical from 10–8 to 10–5 M for
determination of AR agonist activity. 
We performed dose-shift experiments for
the determination of AR antagonist potency
by adding set concentrations of test chemical
(10–7, 10–6, 10–5 M) across a complete
dose–response range of the natural ligand
dihydrotestosterone (DHT). A vehicle control
was included in each experiment (dimethyl sul-
foxide; Sigma) in complete medium. Final con-
centration of dimethyl sulfoxide in medium
was 0.1%. After a 24-hr incubation, treated
cells were rinsed with phosphate-buffered saline
and lysed with 65 µL of lysing buffer (25 mM
tris-phosphate, pH 7.8, 2 mM 1,2-diamino-
cyclohexane-N,N,N´,N´-tetraacetic acid,
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Figure 1. Schematic labeling the main ligand inter-
action features of the natural ligand, dihydrotestos-
terone, with the androgen receptor.
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Figure 2. Structural similarity between known nonsteroidal androgen-receptor antagonists and fenitrothion.
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Fenitrothion10% glycerol, 0.5% Triton X-100, 2 mM
dithiothreitol). Lysate was divided into two 96-
well plates for luciferase and β-galactosidase
activity determination.
Enzyme activity assay. We added luciferase
assay reagent (100 µL; Promega, Madison,
WI, USA) to 20 µL of lysate and determined
luminescence immediately using an ML3000
microtiter plate luminometer (Dynatech
Laboratories, Chantilly, VA, USA). For β-
galactosidase activity determination, 20 µL of a
4 mg/mL solution of chlorophenol red-β-D-
galactopyranoside (CPRG; Sigma) and 150 µL
CPRG buffer (60 mM Na2HPO4, 40 mM
NaH2PO4, 10 mM KCl, 1 mM MgSO4,
50 mM β-mercaptoethanol, pH 7.8) was
added to 30 µL of lysate. Absorbance at 570
nm was determined over a 30-min period
using a Vmax kinetic microplate reader
(Molecular Devices, Menlo Park, CA, USA).
Statistical analysis. Unless otherwise
noted, measured activities presented in this
study represent the means ± SE resulting
from at least three separate experiments with
triplicate wells for each treatment dose. We
analyzed dose–response data using the
sigmoidal dose–response function of the
graphical and statistical program Prism
(GraphPad, San Diego, CA, USA). The equi-
librium dissociation constant (KB) for the
antagonist–receptor complex was determined
by Schild regression analysis of the dose ratio
as previously described (Maness et al. 1998;
McIntyre et al. 2000; Tamura et al. 2001).
The dose ratio is [A´]/[A], where [A´] and [A]
refer to equiactive concentrations of DHT in
the presence and absence of antagonist,
respectively (Kenakin 1993).
Computation of structural properties. We
calculated ligand interatomic distances and
H-bond energies using the SPARTAN mole-
cular modeling software (version 5.1.1 for
UNIX; Wavefunction, Inc., Irvine, CA,
USA). Geometries of studied molecules were
fully optimized using the semiempirical PM3
method (Stewart 1998). To sample the range
of thermodynamically achievable distances
between putative H-bond acceptor sites, lim-
ited conformational space was explored by
constraining the two putative H-bond acceptor
atoms to be a ﬁxed distance apart, allowing the
remainder of the molecule to relax to the low-
est energy conﬁguration, followed by release of
the original constraint allowing full relaxation
in the extended conformation. We tabulated
distances between putative H-bond acceptor
sites, atomic charges at these sites, and total
molecular energies of the conformers. We esti-
mated H-bond interaction energies of the
putative donor and acceptor sites on the nat-
ural AR ligand, DHT, and selected nons-
teroidal analogues using the PM3 method to
compute the energies of interaction with a sin-
gle water molecule at each site; PM3 fully opti-
mized conformations of the water-bound
species were computed for this purpose.
Results
Androgen receptor antagonist activity. We
examined the interaction of a select group of
fenitrothion derivatives with the AR (Table 1).
Mean maximal luciferase activity achieved at
10–7 M DHT across all experiments was
4,889 ± 967 with an interassay coefﬁcient of
variation (CV) of 48%. This represents a 163-
fold induction over background. When exper-
iments were normalized to percent response,
with 100% being the maximal level of induc-
tion within each individual experiment, the
interassay CV in the linear portion of the
curve (5 × 10–7 M DHT) was 13%. At this
same dose (5 × 10–7 M DHT), the within-
assay (replicate wells) CV averaged 17% across
all experiments.
Of the compounds tested in this study,
only methylparathion 3 and ethylfenitrothion 5
demonstrated sufﬁcient AR antagonistic activ-
ity to determine potency in dose-shift experi-
ments (Figure 3). Methylparathion and
ethylfenitrothion both caused parallel shifts in
DHT dose–response curves indicating that,
similar to fenitrothion, they are competitive AR
antagonists. Equilibrium dissociation constants
(KB) (Kenakin 1993) for methylparathion and
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Table 1. Equilibrium dissociation constants (KB) of organophosphate compounds and structurally related
androgen receptor antagonists. 
Chemical namea No. R1 R2 R3 X KB (x 10–8 M)
Fenitrothion 1 CH3 NO2 CH3 S 2.18b
2C H 3 NO2 CH3 ON D c
Methylparathion 3 CH3 NO2 HS 35.9
4C H 3 NO2 HO N D
5C 2H5 NO2 CH3 S 16.5
Ethylparathion 6 C2H5 NO2 HS N D
7C 2H5 CH3 HS N D
8C 2H5 HC H 3 SN D
9C 2H5 (O–CH2–O) S ND
10 n-C3H7 NO2 CH3 SN D
Flutamided 1.07e
Hydroxyﬂutamided 0.22
Linurond 75.8f
aIUPAC chemical names: 1, O,O-dimethyl O-(3-methyl-4-nitrophenyl) phosphorothionate; 2, O,O-dimethyl O-(3-methyl-4-
nitrophenyl) phosphate; 3, O,O-dimethyl O-4-nitrophenyl phosphorothionate; 4, O,O-dimethyl O-4-nitrophenyl phosphate; 5,
O,O-diethyl O-(3-methyl-4-nitrophenyl) phosphorothionate; 6, O,O-diethyl O-4-nitrophenyl phosphorothionate; 7, O,O-
diethyl O-4-methylphenyl phosphorothionate; 8, O,O-diethyl O-3-methylphenyl phosphorothionate; 9, O,O-diethyl O-3,4-
methylendioxyphenyl phosphorothionate; 10, O,O-di-n-propyl O-(3-methyl-4-nitrophenyl) phosphorothionate. bData from
Tamura et al. (2001). cND = KB was not detected at the concentration of 1 × 10–5 M. dRefer to Figure 2 for chemical struc-
tures. eData from Maness et al. (1998). fData from McIntyre et al. (2000).
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Figure 3. Methylparathion and ethylfenitrothion act as competitive reversible inhibitors of AR. HepG2 cells
were transfected with human AR plus an AR-responsive luciferase reporter gene and a constitutively
active β-galactosidase reporter gene (transfection and toxicity control). Transfected cells were treated
with 10–10 to 10–5 M DHT either alone or in combination with 3 x 10–7 M, 10–6 M, and 3 x 10–6 M methyl-
parathion (A) or ethylfenitrothion (B). Values represent the means ± SE of three separate experiments and
are presented as percent response, with 100% activity deﬁned as the activity achieved with 10–7 M DHT
alone in each experiment.
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DHT + 3 × 10–6 M EFNethylfenitrothion were determined as previously
described (Maness et al. 1998; McIntyre et al.
2000; Tamura et al. 2001) and are presented in
Table 1. Cytotoxicity was not observed for any
of the tested compounds in the selected dose
range (data not shown).
Methylparathion 3, which differs from
fenitrothion 1 only by absence of the m-
methyl substitution on the phenyl ring, was
approximately 16-fold less potent than feni-
trothion (Table 1). Similarly, ethylfenitro-
thion 5 demonstrated AR antagonist activity,
whereas ethylparathion 6 gave no detectable
antiandrogenic activity up to a maximum
concentration of 10–5 M (Table 1). These
results indicate that m-methyl substitution
enhances AR antagonist activity of this class
of compounds.
Ethylfenitrothion 5 was 8-fold less potent
than fenitrothion 1 (Table 1). The n-propyl
ester derivative 10 displayed weak AR antago-
nist activity; however, toxicity of this com-
pound > 10–5 M interfered with our ability to
perform experiments necessary to determine
KB. However, the AR antagonist activity of
the n-propyl ester derivative 10 was weaker
than that observed for methylparathion 3
(Table 1). The observation that the antagonist
activity decreases as alkyl chain length
increases indicates that the increase in steric
bulk in the vicinity of thiophosphonyl group
inhibits AR binding afﬁnity.
Oxon derivatives 2 and 4 (Table 1) are
isoelectronic to fenitrothion 1 and methyl-
parathion 3, respectively, and would be
expected to react similarly, and yet these
derivatives showed no antiandrogenic activity
at the highest concentration tested (10–5 M).
Because oxon derivatives of organophospho-
rus compounds are more easily degraded by
hydrolysis than are thiono derivatives (Eto
1974), our results suggest that the oxon deriv-
atives 2 and 4 are unstable under the experi-
mental conditions used in this study.
None of the tested derivatives in which the
nitro group at position R2 (Table 1) was
replaced by a methyl, 7, a hydrogen, 8, or a
methylenedioxy group, 9, gave detectable
antiandrogenic activities up to the highest con-
centration tested (10–5 M). The most obvious
explanation is the lack of hydrogen bond accep-
tor capability at this site in 7 and 8 and the
weaker and more conformationally constrained
H-bond acceptor capability of chlorine in
derivative 9. A metabolite of fenitrothion,
3-methyl-4-nitrophenol, in which the phos-
phothionylester group is cleaved, also showed
no detectable activity (data not shown).
Androgen receptor agonist activity. In
addition to their antagonist activity, hydroxy-
ﬂutamide and fenitrothion have been shown
to have weak agonist activity at high concen-
trations in the absence of effective competi-
tion of the natural ligand (Maness et al. 1998;
Tamura et al. 2001). To explore the structural
basis for this AR agonist activity, we com-
puted steric and electronic properties of puta-
tive H-bond sites for DHT and for four
nonsteroidal compounds with AR agonist and
antagonist activity (Table 2). For each mole-
cule listed in Table 2, the ﬁrst row of numbers
corresponds to properties computed for the
calculated equilibrium geometries (denoted E
= 0.0 kcal/mol). In addition, the first two
columns of data indicate the relative energy
cost (from equilibrium) required to achieve a
ﬁxed nonequilibrium distance (x—z) between
the most distant H-bond centers. All five of
these molecules have some degree of ﬂexibil-
ity and can achieve shortening (in the case of
DHT) or lengthening (in the case of the
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Table 2. Calculated properties of dihydrotestosterone (DHT) in relation to fenitrothion and known androgen antagonists.
Relative energy Distance (Å)b Atomic chargec H bond (kcal/mol)d
Chemical structure (kcal/mol)a x – – – zx y z x yz
0.00 10.48 –0.31 –0.30 –3.70 –3.14
0.36 10.00 (1.81 Å) (1.82 Å)
0.00 8.18 –0.60 –0.58 –0.59 –3.33 –0.17 –2.17
1.68 9.50 (1.83 Å) (1.88 Å) (2.83 Å)
(8.09)e
0.00 7.50 –0.58 –0.33 –2.91 –2.97
2.48 8.00 (1.85 Å) (1.82 Å)
0.00 8.94 –0.58 –0.35 –0.31 –2.96 –3.20 –2.95
1.72 9.50 (1.83 Å) (1.81 Å) (1.83 Å)
(7.27)e
0.00 9.16 0.09 –0.34 –0.22 –2.06 –3.25 –2.85
1.65 9.50 (2.64 Å) (1.82 Å) (2.68 Å)
(7.00)e
aRelative energies of PM3 (Stewart, 1998) optimized geometries; E = 0.00 kcal/mol corresponds to fully optimized equilibrium conﬁguration; whereas second energy corresponds to energy
when x—z distance is constrained (e.g., 10 Å for DHT) and rest of molecule is allowed to relax. bDistance between most separated H-bonding centers (O or S) in equilibrium or constrained
conﬁguration. cPM3 Mulliken atomic charges at equilibrium geometry. dH-bond interaction energies, E(product)-E(water)-E(ligand), computed using PM3 method, using fully optimized
structures of water, ligand, and merged water–ligand product. eDistance of x—y H-bonding centers corresponding to the constrained conﬁguration with x—z distance of 9.5 Å.
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DHTother four molecules) of the distance between
H-bond centers with relatively little energy
cost. However, all four of the nonsteroidal
compounds fall short of the ≥ 10 Å separa-
tion of H-bond centers calculated for DHT.
Of the four, ﬂutamide has the shortest com-
puted distance (8 Å) between H-bond oxygen
centers, falling a full 2 Å short of the DHT
template for the AR ligand binding interac-
tion. Each of the remaining three nons-
teroidal compounds can achieve a relatively
stretched configuration (9.5 Å between the
most distant H-bond centers) with small
energy cost (< 1.8 kcal/mol), to within 0.5 Å
of the lower bound for DHT. Of these three
compounds, only linuron has no measurable
agonist activity (McIntyre et al. 2000).
An important structural and functional
distinction between fenitrothion and DHT is
the thiol as a putative H-acceptor center in
fenitrothion versus the C17β hydroxyl in
DHT. Estimated energies and distances asso-
ciated with H bonds formed between a water
molecule and possible H-bond sites are listed
in the last three columns of Table 2.
Comparison of the calculated H-bond energies
and distances corresponding to the most dis-
tant z center for fenitrothion and hydroxy-
ﬂutamide indicates a smaller H-bond energy
for the sulfur (–2.17 vs. –2.95 kcal/mol), but
also a 1 Å longer H-bond distance (2.83 vs.
1.83 Å). Hence, the smaller H-bond interac-
tion energy may be offset by a more easily
achieved H-bond distance for fenitrothion ver-
sus hydroxyﬂutamide. If the extra 1 Å H-bond
distance is factored into the overall distance
between H-bond centers, fenitrothion extends
to the 10 Å range of the DHT template.
Discussion
The present study focused on identifying and
characterizing the structural basis for the
interaction of organophosphorus-related
chemicals with the AR. In attempting to fur-
ther elucidate the AR binding mechanism of
organophosphorus-like ligands, such as feni-
trothion, it is important to consider a pro-
posed binding mechanism in the context of
what is known generally about steroid hor-
mone receptor function, as well as speciﬁcally
about polar residue interactions of bound lig-
ands in the AR-LBD.
A “mouse trap” mechanism based on
crystallographic studies of ligand-binding
interactions has been proposed as a model for
ligand-receptor binding within the nuclear
steroid hormone superfamily (Brzozowski et
al. 1997; Buchanan et al. 2001; Goldstein et
al. 1993; Renaud et al. 1995; Wurtz et al.
1996). Brieﬂy, the ligand is trapped from the
bulk solution at the entrance of the ligand-
binding pocket and brought into and locked
at the binding site by interaction with amino
acid residues within the receptor through
H-bond and hydrophobic interactions. This
leads to formation of an AR homodimer with
two bound ligands, which induces additional
conformational transitions leading to a more
compact receptor structure and a transcrip-
tionally active ligand-receptor homodimer
complex. The speciﬁcs of the ligand binding
interaction vary with each of the nuclear
steroid hormone receptors, but in all cases the
carboxy-terminal helix 12 appears to play a
crucial role in determining agonist or antago-
nist activity. In the case of a bound agonist,
helix 12 acts as a “lid” that swings around to
entrap the ligand in the LBD, effecting the
necessary conformational change for tran-
scription to occur (Brzozowski et al. 1997;
Buchanan et al. 2001; Matias et al. 2000). In
the case of a bound antagonist, the helix 12
lid is prevented from closing and the entrance
to the LBD remains open, thus preventing
transcriptional activation (Brzozowski et al.
1997; Buchanan et al. 2001; Marhefka et al.
2001; Pike et al. 1999). With retinoic acid
(Figure 2) and retinoid X receptors (RXR), it
is believed that the carboxylate group of
retinoic acid enters the ligand-binding pocket
ﬁrst and is drawn down the hydrophobic cleft
to its anchoring site. Both the H bond at the
carboxylate group site and Van der Waals
interaction at the β-ionone ring site stabilize
the ligand (Renaud et al. 1995; Wurtz et al.
1996). Likewise, for 17β-estradiol (Figure 2),
the 3-OH group of the A-ring and the C17β
hydroxylic oxygen of the D-ring both act as
anchoring elements and H-bond donors
within ERα (Brzozowski et al. 1997; Pike et
al. 1999; Tanenbaum et al. 1998). For the
DHT-AR interaction, the carbonyl oxygen of
the A-ring acts as an H-bond acceptor,
whereas the C17β hydroxylic oxygen of the
D-ring could act as either an H-bond donor
or acceptor (Figure 2) (Marhefka et al. 2001;
Matias et al. 2000).
Speciﬁcally in reference to the AR-LBD, it
had been inferred from DNA sequence
homology (Wurtz et al. 1996) and mutation
studies (Doesburg et al. 1997; Gottlieb et al.
1998; Taplin et al. 1999; Wurtz et al. 1996)
that the carbonyl oxygen of the A-ring and the
C17β hydroxylic oxygen of the D-ring in
DHT most likely interact through H-bonds
with Arg752 in helix 5 and Thr877 in helix 11
in AR-LBD, respectively, because mutation of
these residues caused a complete androgen-
insensitivity syndrome (Sultan et al. 1993)
and altered ligand specificity (Veldscholte et
al. 1990). Recent crystallographic determina-
tion of the AR-LBD bound to a steroidal-type
ligand (R1881), and a more recent homology
modeling study that considered a variety of
nonsteroidal AR ligands bound to the LBD,
provide evidence to support and refine this
view (Marhefka et al. 2001; Matias et al.
2000). Both studies reported H-bonding
interactions of the A-ring polar group of
bound AR ligands with Arg752, mediated by
one or two bound water molecules. On the
opposite terminus of the molecule, the crystal-
lographic study provided evidence of H bond-
ing between the C17β hydroxyl group of
R1881 with two polar residues: the carbonyl
oxygen of Asn705 and the hydroxyl oxygen of
Thr877 (Matias et al. 2000). The subsequent
AR homology study (Marhefka et al. 2001)
considered a broader variety of bound nons-
teroidal ligands and found different possible
binding modes within this C17β-OH region,
indicating the possibility of either an H-bond
donor or acceptor interaction of the ligand
with Thr877. Hence, we propose that the
mechanism for the fenitrothion thiol to act as
an H-bond acceptor in the D-ring 17β-OH
region of the AR-LBD likely involves interac-
tion with the Thr877 residue of helix 11. We
speculate further that the amide nitrogen of
Asn705 could possibly act as an H-bond donor
in interaction with the fenitrothion thiol.
Comparison of a putative three-dimensional
binding orientation of fenitrothion compared
to DHT in the AR-LBD is represented
schematically in Figure 4.
Regarding the mechanism of activation of
the AR by agonist ligands, Thr877 is located
within helix 11 in close apposition to helix 12.
We speculate that by establishing favorable
interactions with Thr877 (as well as other
residues within this domain, specifically
Asn705), the ligand effectively stabilizes this
region of the AR. The result is to enhance the
overall probability of helix 12 favorably ori-
enting into an activated position. Analysis of
two independently elucidated crystal struc-
tures of the AR [Protein DataBank (PDB)
accession numbers 1I38 (Sack et al. 2001)
and 1E3G (Matias et al. 2000)] reveals a dis-
tance of approximately 15.2 Å between the
H-bonded terminal nitrogen of Arg752 and
the hydroxyl oxygen of Thr877, thus provid-
ing requisite dimensions within the AR-LBD
(Figure 5). Allowing a maximum of 2.5–3.0
Å from each of these atoms to form stable H
bonds suggests a separation distance of
9.2–10.2 Å between H-bonding groups pre-
sent on candidate ligands, with the lesser of
these values approaching the limit of stability
for H bonding. It can be inferred that 
ligands that are unable to achieve thermody-
namically stable conformations within these
dimensional constraints will have reduced
capacity to transcriptionally activate the AR
and produce agonist effects.
The present analysis considers the confor-
mationally stretched distance between polar
H-bond capable sites of known AR antago-
nists to be a measure of the potential of a
molecule to express additional agonist proper-
ties. We henceforth refer to this as the “near-
10 Å polar interactions rule.” Why is it
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erties if these appear secondary to antagonist
activity and are detected only at high doses in
the absence of effective competition with nat-
ural ligand (Maness et al. 1998; Tamura et al.
2001)? How can we interpret this informa-
tion mechanistically and in the context of a
risk evaluation? Referring to the schematic
representation of the AR-LBD in Figure 4,
we consider the three main binding elements
likely required for antagonist and/or agonist
activity. In common with other known AR
antagonists, fenitrothion and its organophos-
phorus-like AR antagonist analogues all con-
tain the essential A-ring phenyl feature with a
putative strong H-bond interaction site. We
posit that structures that can achieve, in addi-
tion, effective hydrophobic and steric interac-
tions in the central binding region of the
LBD are necessary for AR antagonism.
Recent elucidation of the AR-LBD with
bound ligands confirms a central binding
region of nonpolar residues that is predicted
to tolerate more bulky, hydrophobic sub-
stituents (Marhefka et al. 2001; Matias et al.
2000). However, structural constraints are
clearly important for conferring sufﬁcient and
optimum binding afﬁnity to produce antago-
nism. This contention is supported by the
results of an earlier study aimed at designing
high-afﬁnity nonsteroidal antiandrogens with
purely antiandrogenic activity for clinical
application (i.e., with no agonist effects or
cross hormonal interactions) (Teutsch et al.
1994). Selected members of the class of N-
substituted-arylthiohydantoins, analogues of
the common antiandrogen therapeutic agent
nilutamide, were found to have exceptionally
high relative binding afﬁnities to the AR, sim-
ilar to DHT. The structural modifications
from previously known antagonists were pri-
marily in the D-ring region, involving a
thioamide replacement of an amide. These
compounds did not, however, provide a good
candidate feature for D-ring H-bond interac-
tion according to the “near-10 Å polar inter-
actions rule” (the thiol was computed to be a
7.5 Å separation from the A-ring H-bond
acceptor site), which is consistent with lack of
reported agonist properties.
The importance of essential structural ele-
ments in the central binding region is also
supported by the observed 15-fold increase in
binding affinity for fenitrothion versus
methylparathion upon A-ring substitution of
a hydrogen for a methyl at the R3 A-ring posi-
tion (see Table 1). Previous authors suggested
that electron-withdrawal properties of the R3
phenyl substituent enhancing the H-bond
acceptor capability at the R2 position are
important for antagonism (Singh et al. 2000;
Teutsch et al. 1994; Tucker et al. 1988). In
contrast, the authors of a recent AR homology
study counter that the steric/hydrophobic
interaction aspects of this substituent are more
important components for binding (Marhefka
et al. 2001), a view more consistent with the
present ﬁndings.
For the last of the three AR-LBD binding
elements, multiple lines of evidence implicate a
strong H-bond interaction in the vicinity of
the D-ring (C17β-OH) LBD binding region
as being a necessary, but not sufﬁcient, require-
ment for AR agonist activity. SAR evidence
gathered from previous study of an extensive
series of nonsteroidal antiandrogens (Tucker et
al. 1988), some with both agonist and antago-
nist properties, is consistent with this view. In
that study, more than 70 compounds were
synthesized and tested, all 3-(substituted thio)-
2-hydroxypropionanilides (HPAs) containing
the essential structural moiety illustrated in
Figure 2 with an additional polar hydroxyl
substituent on X. A key ﬁnding of that study in
relation to the present work is that the electron-
withdrawing capability of the substituent oppo-
site to the hydroxyl group on X determined
whether the molecule had agonist effects in
addition to antagonist effects: Compounds
with CF3 substituents were agonists/antago-
nists, whereas the same compounds with CH3
substituents had no agonist properties and a 2-
to 3-fold reduction in antagonism. The clear
implication is that the X-OH becomes a
stronger H-bond donor with the additional
CF3 substituent and therefore, is more likely to
enhance the D-ring region interaction neces-
sary to produce agonism. In comparison to our
own work, the HPAs can be viewed as struc-
turally analogous to hydroxyflutamide, with
the same essential structural moiety yielding
the same distance separations between H-bond
capable polar groups as in hydroxyflutamide
(Figure 2 and Table 2). Hence, all of the
HPAs examined satisfy our proposed distance
requirement for potential C17β-OH region
interaction, and all are reportedly antagonists,
but only those chemicals with sufficiently
strong H-bond interaction potential in the D-
ring region have additional agonist activity.
A recent study that considered the bind-
ing of steroidal and nonsteroidal ligands to a
double mutant form of the AR sheds further
light on the multiple factors controlling the
potential for a ligand to exhibit AR agonism
(Matias et al. 2002). Mutations of Thr877
(Ala) and Leu701 (His) in the D-ring region
were shown to inhibit binding of the natural
ligand, DHT, and to significantly enhance
binding and agonist properties of steroidal
cortisols, as well as hydroxyflutamide.
Crystallographic evidence, as well as energy
minimization calculations, indicates that the
altered residues in the double mutant AR sig-
nificantly reduce unfavorable steric interac-
tions of these bound ligands in the D-ring
region (i.e., interactions that normally pre-
vent or inhibit helix 12 closure and agonism
in the wild-type AR) (Matias et al. 2002).
Particularly with regard to agonistic activity
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Figure 4. Schematic representation of the androgen receptor ligand binding domain comparing proposed
binding configurations of DHT (thin-line structure) and fenitrothion (thick-line structure), with distances
between H-bond centers indicated for each.
Hydrophobic
region
H-bond donor
region
H-bond donor
region
H2N-C-NH-Arg752
N-H
Thr877
H-O
A-ring
D-ring
9.5 Å
10.4 Å Figure 5. Representation of the DHT-bound AR-LBD
derived from crystal structure coordinates (Matias
et al. 2000; Sack et al. 2001), showing the distance
between putative H-binding sites on the residues
Arg752 and Thr877, and in relation to the locations of
helices 11 and 12. [Figure generated using Insight
2000 (Accelrys, Inc), kindly provided by S. Keenan.]
Helix 11
Helix 12
15.2 Å
Arg752
Thr877of hydroxyflutamide under different experi-
mental conditions, these results indicate fur-
ther modulation and sensitivity of agonism to
subtle steric and conformational inﬂuences in
the D-ring binding region.
The implication of these arguments is that
fenitrothion, because it is capable of acting
either as an AR antagonist or agonist, depend-
ing on the experimental conditions (competi-
tive or noncompetitive binding), is capable of
satisfying all three binding requirements for
AR-LBD interaction, but only under selected
conditions. With no reported evidence to
suggest allosteric binding mechanisms for AR
activity, and evidence pointing to the ability
of nonsteroidal AR ligands to effectively bind
in the AR-LBD (Marhefka et al. 2001), we
posit that AR agonism is only observed at
high doses of ligand due to the probabilistic
nature of the AR binding interaction. The
probability of initially encountering the AR
has a ﬁrst-order dependence on dose of ligand
(Pe). Second is the probability of being drawn
into the AR-LBD cavity and binding in some
fashion (Pb); fenitrothion likely has a lower
Pb than the natural DHT ligand due to sub-
optimal binding affinity in the A-ring and
central hydrophobic regions. Finally, the con-
formational flexibility of fenitrothion and
other nonsteroidal AR ligands introduces a
third probabilistic component. In the partially
AR-bound state, fenitrothion has a less than
unit probability (Ps) of achieving the stretched
conﬁguration for optimal H-bonding interac-
tion in the C17β hydroxyl region that is pre-
sumed necessary for AR transcriptional
activity; achieving this configuration will
depend on the local molecular dynamics
forces within the AR-LBD. Hence, with sub-
optimal binding (i.e., satisfying only two of
the three binding elements), antagonism is the
predicted and more probable outcome (the
product of the fractional probabilities Pe ×
Pb). Because agonism requires the third bind-
ing element also be achieved (i.e., the “near-
10 Å polar interactions rule”), it is a less
probable event (i.e., Pe × Pb × Ps). Because
overall probabilities for observing either antag-
onism or agonism increase with increasing
dose of fenitrothion (i.e., Pe), the overall prob-
ability of observing agonism, if achievable, will
be greatest at the highest fenitrothion doses.
The implications for hazard assessment are
that nonsteroidal chemicals should be
screened for all three of the binding elements
for AR-LDB interaction, and those com-
pounds predicted to satisfy all three elements
and effect transcription (i.e., act as agonists)
may be of greater concern.
A ﬁnal point concerns the comparison of
different quantitative and qualitative measures
of androgenic activity across a variety of assays
and test systems for the purposes of generating
SAR hypotheses and prediction models. If
quantitative activities (e.g., relative binding
afﬁnities) are used in deriving a potency predic-
tion model, clearly these must be for a validated
and uniform measure of androgenic activity.
Unfortunately, the available data are not uni-
form in this sense and represent a variety of
measures across a variety of test systems (e.g.,
Singh et al. 2000). This accounts for the rela-
tively limited data sets used in previously
reported QSAR models for predicting andro-
genic activity of environmental chemicals. For
the purposes of qualitative identification of
important SAR features and structural elements
relative to AR activity, however, we believe that
comparisons can be made across diverse data
sets provided that one uses only relative infor-
mation extracted from within those data sets
(e.g., in considering the structural features that
distinguish agonist from antagonist activity
among the HPAs) (Tucker et al. 1988). Prior
SAR investigations aimed at understanding and
optimizing the activity of nonsteroidal antian-
drogens contain a wealth of potentially useful
information (Singh et al. 2000; Teutsch et al.
1994; Tucker et al. 1988). These data can and
should be considered in efforts to generate use-
ful hypotheses and appropriate model con-
straints for screening of environmental
compounds for potential androgenic activity.
The results of this study have important
implications for future attempts to construct
SAR models for predicting potential andro-
genic activity. First, conformational ﬂexibility
of potential ligands should be considered in
light of the determining constraints for opti-
mal AR interaction—namely, the ability to
achieve a suitable distance separation of polar
interaction groups (approximately 10 Å) at
low energy cost. If conformational ﬂexibility is
not taken into account, AR homology models
and other types of SAR screens may fail to
detect the potential for AR binding interac-
tion. Second, the demonstrated AR antagonist
activities of fenitrothion, methylparathion (3),
and ethylfenitrothion (5) provide compelling
evidence that the thiophosphonyl group bears
sufﬁcient analogy to the hydroxylamide moi-
ety of hydroxyﬂutamide as to similarly satisfy
AR-LBD binding elements for both antago-
nism and agonism. This is despite the differ-
ent H-bonding interactions predicted for the
thiol H-bond acceptor in fenitrothion versus
the hydroxyl H-bond donor in hydroxyflu-
tamide or DHT within the AR-LBD. Third,
the results reported in Table 1 for a series of
organophosphorus-like chemicals point to
structural features that either determine or
enhance the ability of these compounds to act
as AR antagonists. These results expand our
knowledge of structural binding elements that
can be accommodated by the AR-LBD and
that should be considered in future efforts to
develop general screens for AR activity of
environmental chemicals.
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